Asset Details
Do you wish to reserve the book?
The Health Economics of Bladder Cancer: An Updated Review of the Published Literature
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
The Health Economics of Bladder Cancer: An Updated Review of the Published Literature
Do you wish to request the book?
The Health Economics of Bladder Cancer: An Updated Review of the Published Literature
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
The Health Economics of Bladder Cancer: An Updated Review of the Published Literature
2014
Overview
The purpose of this paper is to provide a current view of the economic burden of bladder cancer, with a focus on the cost effectiveness of available interventions. This review updates a previous systematic review and includes 72 new papers published between 2000 and 2013. Bladder cancer continues to be one of the most common and expensive malignancies. The annual cost of bladder cancer in the USA during 2010 was $US4 billion and is expected to rise to $US5 billion by 2020. Ten years ago, urinary markers held the potential to lower treatment costs of bladder cancer. However, subsequent real-world experiments have demonstrated that further work is necessary to identify situations in which these technologies can be applied in a cost-effective manner. Adjunct cytology remains a part of diagnostic standard of care, but recent research suggests that it is not cost effective due to its low diagnostic yield. Analysis of intravesical chemotherapy after transurethral resection of bladder tumor (TURBT), neo-adjuvant therapy for cystectomy, and robot-assisted laparoscopic cystectomy suggests that these technologies are cost effective and should be implemented more widely for appropriate patients. The existing literature on the cost effectiveness of bladder cancer treatments has improved substantially since 2000. The body of work now includes many new models, registry analyses, and real-world studies. However, there is still a need for new implementation guidelines, new risk modeling tools, and a better understanding of the empirical burden of bladder cancer.
Publisher
Springer International Publishing,Adis International,Springer,Springer Nature B.V
Subject
/ Antineoplastic Agents - economics
/ Antineoplastic Agents - therapeutic use
/ Biological and medical sciences
/ Health and social institutions
/ Humans
/ Medicare
/ Medicine
/ Nephrology. Urinary tract diseases
/ Patients
/ Pharmacoeconomics and Health Outcomes
/ Pharmacology. Drug treatments
/ Public health. Hygiene-occupational medicine
/ Studies
/ Tumors of the urinary system
/ Urinary Bladder Neoplasms - diagnosis
/ Urinary Bladder Neoplasms - drug therapy
/ Urinary Bladder Neoplasms - economics
/ Urinary Bladder Neoplasms - surgery
/ Urinary Bladder Neoplasms - therapy
